smpСкорая медицинская помощьEMERGENCY MEDICAL CARE2072-6716Northwest State Medical University named after II Mechnikov10.24884/2072-6716-2017-18-2-37-44smp-206Research ArticleОБЗОРЫREVIEWSСОВРЕМЕННАЯ ТАКТИКА ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ ВЕНОЗНЫХ ТРОМБОЗОВ И ТРОМБОЭМБОЛИЙ. РОЛЬ НОВЫХ ПЕРОРАЛЬНЫХ АНТИКОАГУЛЯНТОВ. Часть IA MODERN APPROACH TO THE TREATMENT AND PROPHYLAXIS OF VENOUS THROMBOEMBOLISM. THE ROLE OF NEW ORAL ANTICOAGULANTS. Part IШальневВ. И.ShalnevV. I.

Санкт-Петербург 

Контакт: Шальнев Владимир Ильич

vshalnev@gmail.comСеверо-Западный государственный медицинский университет им. И.И. МечниковаРоссияNorth-Western State Medical University named after I. I. MechnikovRussian Federation2017171020171823744Copyright © Шальнев В.И., 20172017Шальнев В.И.Shalnev V.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://smp.spb.ru/jour/article/view/206

В статье рассматривается проблема венозных тромбозов и тромбоэмболий в клинической практике как об одной из основных причин сердечно-сосудистой смертности и инвалидизирующих инсультов. Анализируются современные подходы к лечению и профилактике тромбозов и тромбоэмболий в различных клинических ситуациях, приводятся данные последних национальных и международных рекомендаций по этой теме. Излагаются сравнительные данные по применению традиционных антитромботических средств и новых пероральных антикоагулянтов (дабигатрана, апиксабана и ривароксабана) при лечении и профилактике тромбозов. Анализируются результаты наиболее важных рандомизированных клинических исследований в данной области. 

The article highlights the burden of the venous thromboembolism (VTE) in clinical practice as one of the most frequent cause of cardiovascular death and disabling embolic stroke worldwide. The author compares the traditional use of VKA antagonists and new class of oral anticoagulants— direct thrombin and factor Xa inhibitors (dabigatran, rivaroxaban, apixaban) for VTE treatment and prevention. The results of most significant randomized clinical trials in VTE area and the latest international guidelines are also discussed. 

венозный тромбозтромбоэмболииантикоагулянтыvenous thrombosisthromboembolismanticoagulantsReferencesРоссийские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений // Флебология. 2015. Т. 9. № 4. С. 4–46. [Rossiiskie klinicheskie rekomendatsii po diagnostike, lecheniyu I profilaktike venoznikh tromboembolicheskich oslojnenii. Flobologiya, 2015, Vol. 9 (4), рр. 4–46. (In Russ.)].Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений // Флебология. 2015. Т. 9. № 4. С. 4–46. [Rossiiskie klinicheskie rekomendatsii po diagnostike, lecheniyu I profilaktike venoznikh tromboembolicheskich oslojnenii. Flobologiya, 2015, Vol. 9 (4), рр. 4–46. (In Russ.)].Mazzolai L., Aboyans V., Ageno W. et al. Diagnosis and Management of Acute Deep Vein Thrombosis: A Joint Consensus Document from European Society of Cardiology, Working Groups of Aorta and Peripheral Circulation and Pulmonary Circulation. Eur. Heart J., 2017, Feb 17 [Epub ahead of print.Mazzolai L., Aboyans V., Ageno W. et al. Diagnosis and Management of Acute Deep Vein Thrombosis: A Joint Consensus Document from European Society of Cardiology, Working Groups of Aorta and Peripheral Circulation and Pulmonary Circulation. Eur. Heart J., 2017, Feb 17 [Epub ahead of print.Thrombosis: a major contributor to the global disease burden. ISTH Steering Committee for World Thrombois Day. J. Thromb. Haemost., 2014, Vol. 12, рр. 1580–1590.Thrombosis: a major contributor to the global disease burden. ISTH Steering Committee for World Thrombois Day. J. Thromb. Haemost., 2014, Vol. 12, рр. 1580–1590.White R. The Epidemiology of Venous Thromboembolism. Circulation, 2003, Vol. 107, рр. 14–18.White R. The Epidemiology of Venous Thromboembolism. Circulation, 2003, Vol. 107, рр. 14–18.Rosamond W., Flegal K., Furie K. et al. Heart disease and stroke statistics 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation, 2008, Vol. 117, рр. 25–46.Rosamond W., Flegal K., Furie K. et al. Heart disease and stroke statistics 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation, 2008, Vol. 117, рр. 25–46.Connolly S., Pogue J., Hart R. et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet, 2006, Vol. 367, рр. 1903–1912.Connolly S., Pogue J., Hart R. et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet, 2006, Vol. 367, рр. 1903–1912.Oden A., Fahlen M., Hart RG. Optimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisal. Thrombosis Research., 2006, Vol. 117, рр. 493–499.Oden A., Fahlen M., Hart RG. Optimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisal. Thrombosis Research., 2006, Vol. 117, рр. 493–499.Gladstone D.J., Bui E., Fang J. et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke, 2009, Vol. 40, рр. 235–240.Gladstone D.J., Bui E., Fang J. et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke, 2009, Vol. 40, рр. 235–240.Connolly S.J., Ezekowitz, M., Yusuf S. et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. New Engl. J. Med., 2009, Vol. 361, рр. 1139–1151.Connolly S.J., Ezekowitz, M., Yusuf S. et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. New Engl. J. Med., 2009, Vol. 361, рр. 1139–1151.Patel M.R., Mahaffey K.W., Garg J. et al. for the ROCKET AF Investigators. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. New Engl. J. Med., 2011, Vol. 365, рр. 883–891.Patel M.R., Mahaffey K.W., Garg J. et al. for the ROCKET AF Investigators. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. New Engl. J. Med., 2011, Vol. 365, рр. 883–891.Granger C. B., Alexander J. H., McMurray J.V. et al. for the ARISTOTLE Investigators. Apixaban versus Warfarin in Patients with Atrial Fibrillation. New Engl. J. Med., 2011, Vol. 365, рр. 981–992.Granger C. B., Alexander J. H., McMurray J.V. et al. for the ARISTOTLE Investigators. Apixaban versus Warfarin in Patients with Atrial Fibrillation. New Engl. J. Med., 2011, Vol. 365, рр. 981–992.Romanelli R.J., Nolting L.R., Dolginsky M. et al. Dabigatran Versus Warfarin for Atrial Fibrillation in RealWorld Clinical Practice. Circulation: Cardiovascular Quality and Outcomes. 2016, Vol. 9, рр. 115.Romanelli R.J., Nolting L.R., Dolginsky M. et al. Dabigatran Versus Warfarin for Atrial Fibrillation in RealWorld Clinical Practice. Circulation: Cardiovascular Quality and Outcomes. 2016, Vol. 9, рр. 115.Yao X., Abraham N.S., Sangaralingham L.R. et al. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation. J. of Am. Heart Association, 2016, Vol. 5, e003725.Yao X., Abraham N.S., Sangaralingham L.R. et al. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation. J. of Am. Heart Association, 2016, Vol. 5, e003725.2016 ESC Guidelines for the management of atrial fibrillation. Eur. Heart J. 2016, Vol. 37, рр. 2893–2962.2016 ESC Guidelines for the management of atrial fibrillation. Eur. Heart J. 2016, Vol. 37, рр. 2893–2962.2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation. Eur. Heart J., 2016, Vol. 37, рр. 267–315.2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation. Eur. Heart J., 2016, Vol. 37, рр. 267–315.Mega J.l., Braunwald E., Wiviott D.S. et al. for the ATLAS— TIMI-51 Investigators/Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. New Engl. J. Med., 2012, Vol. 366, рр. 9–19.Mega J.l., Braunwald E., Wiviott D.S. et al. for the ATLAS— TIMI-51 Investigators/Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. New Engl. J. Med., 2012, Vol. 366, рр. 9–19.

The authors declare that there are no conflicts of interest present.